PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor-Reference-Cited by-同舟云学术

PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor

Published:2019-05-13 Issue:6 Volume:14 Page:1235-1242
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Xu Hua¹,Jesson Michael I.²,Seneviratne Uthpala I.¹,Lin Tsung H.³,Sharif M. Nusrat³,Xue Liang⁴,Nguyen Chuong⁵,Everley Robert A.⁵,Trujillo John I.⁵,Johnson Douglas S.¹,Point Gary R.⁶,Thorarensen Atli¹,Kilty Iain³,Telliez Jean-Baptiste³^ORCID

Affiliation:

1. Medicine Design, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States

2. Drug Safety R&D, Pfizer Worldwide R&D, 300 Technology Square, Cambridge, Massachusetts 02139, United States

3. Inflammation and Immunology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States

4. Integrative Biology, Pfizer Worldwide R&D, 610 Main Street, Cambridge, Massachusetts 02139, United States

5. Medicine Design, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States

6. Drug Safety R&D, Pfizer Worldwide R&D, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.9b00188

Reference27 articles.

1. Cytokine Signaling Modules in Inflammatory Responses

2. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases

3. New insights into the regulation of T cells by γc family cytokines

4. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)

5. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease;Cytokine & Growth Factor Reviews;2024-10

2. Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis;Dermatology and Therapy;2024-09-10

3. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

4. Unravelling the Impact of Process Impurities on the Crystallization of Ritlecitinib Tosylate Using Molecular Dynamics;Organic Process Research & Development;2024-09-09

5. Ritlecitinib in severe alopecia areata: a profile of its use;Drugs & Therapy Perspectives;2024-09